Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Alex Edelman-Pool/Getty Images
The Trump administration's plan for lowering prescription drug costs does not include many new steps to bring down the actual price of drugs. Instead, it largely targets other parts of the health care system and re-emphasizes existing efforts to lower costs through more competition.
Key quote: “We are very much eliminating the middlemen," President Trump said in a Rose Garden speech unveiling the plan. And that's where most of its emphasis lies. It entertains the idea of new price disclosures and reshuffling some of the discounts that various middlemen negotiate off of drugs' sticker prices. But when it comes to reducing those sticker prices, Trump's plan leans heavily on more competition from generic drugs — an initiative that's already in progress at the FDA.